Anthea Pharma's Bupivacaine Hydrochloride ANDA220493 Receives AP Status
The FDA has granted an Abbreviated New Drug Application (ANDA) approval status for Bupivacaine Hydrochloride submitted by Anthea Pharma.
Asset / Drug
Drug and asset intelligence for Anthea with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.